Beijing Luzhu Biotechnology Co., Ltd. provided consolidated earnings guidance for the six months ended June 30, 2023. It is expected that the Group will experience a significant decrease in net loss and a decrease in adjusted net loss for the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The group expects to record a net loss of not more than RMB 80 million for the six months ended June 30, 2023, representing a decrease of not less than 87% as compared to the net loss of approximately RMB 652 million for the six months ended June 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.2 HKD | -0.49% |
|
+2.12% | -32.44% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.44% | 524M | |
+0.85% | 92.38B | |
-3.03% | 37.9B | |
-10.46% | 33.73B | |
+74.71% | 27.98B | |
-13.39% | 15.86B | |
-1.08% | 13.97B | |
-11.15% | 11.67B | |
+169.04% | 10.17B | |
-50.19% | 10.04B |
- Stock Market
- Equities
- 2480 Stock
- News Beijing Luzhu Biotechnology Co., Ltd.
- Beijing Luzhu Biotechnology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023